Trestle Biotherapeutics · Mar 2025
Trestle announced a research collaboration with Humacyte to explore integrating Trestle’s biofabricated kidney tissues with Humacyte’s ATEV technology to generate vascularized bioengineered kidneys.
Bioengineered kidneys for patients with kidney failure
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Trestle Biotherapeutics is a preclinical biotechnology company founded in 2020 that is developing bioengineered, stem cell-derived kidney tissues intended to reduce or eliminate dialysis dependence for patients with end-stage renal disease. Public sources place it in La Jolla / San Diego, California. No public GitHub or X profile was found in the sourced materials.
Primary product
An implantable bioengineered kidney tissue / therapeutic tissue for end-stage renal disease
Founded
2020
Headquarters
9310 Athena Circle, La Jolla, CA 92037, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Regenerative medicine / kidney therapeutics
Offices
9276 Scranton Road, San Diego, CA 92121
San Diego, California, United States
Business model
Preclinical therapeutic R&D
Grant- and prize-funded development
Research collaborations
Licensing of foundational IP
Funding
Stage
Seed
Total raised
$1.1M
Latest round
KidneyX Artificial Kidney Prize · Jun 2023
Latest amount
$1M
KidneyX Artificial Kidney Prize
Jun 2023 · KidneyX Innovation Accelerator
May 2023 · Wellcome Leap
Apr 2021 · Acequia Capital
Mar 2021
Jan 2021 · Y Combinator
Dec 2020
People & investors
Work & culture
Mission-driven, early-stage and research-heavy; the company emphasizes ambitious, hands-on lab work, collaboration, and aggressive timelines.
Compensation
Public salary estimates suggest average annual pay of about $96,208, with a typical range of $84,616 to $108,794 as of June 2026; job postings also describe a competitive salary and comprehensive benefits package.
Benefits
Competitive salary
Comprehensive benefits package
401(k)
Healthcare
Disability insurance
Pension
Product & market
Pricing
Not publicly disclosed
Differentiators
- —Implantable bioengineered kidney tissue approach
- —Stem cell-derived therapeutic tissue
- —Combines 3D biofabrication with kidney biology
- —Aims to replace dialysis rather than only manage symptoms
- —Licensed foundational technologies from Harvard and Kumamoto University
- —Research collaboration path toward vascularized organs
Technology
Stem cell biology
3D biofabrication
3D bioprinting
Fluidics
Cell manufacturing
Kidney organoids
Biomaterials
Hydrogels
Microfluidic systems
Bioreactors
In vitro functional assays
AI/ML-assisted workflow tools
Customers
Patients with end-stage renal disease
Dialysis-dependent kidney-failure patients
Future transplant candidates
Competitors
Aurinia Pharmaceuticals
Akebia Therapeutics
Calliditas Therapeutics
Nephrogen
Walden Biosciences
Renibus Therapeutics
Scale & contact
Latest news
Trestle Biotherapeutics · Jun 2023
Trestle received a $1 million prize from the KidneyX Artificial Kidney Prize program to advance preclinical R&D on bioengineered kidney tissues.
Trestle Biotherapeutics · May 2023
Trestle joined the HOPE program, a Wellcome Leap initiative focused on bioengineering complex human organs and immune-system interactions.
BioSpace · Feb 2022
Trestle announced an advisory board with academic and industry leaders in 3D biofabrication, stem cells, tissue engineering, immunology, and nephrology.
Trestle Biotherapeutics · Jan 2021
Trestle joined Y Combinator’s Winter 2021 cohort and received early financial and strategic support from YC.
Jobs and careers at Trestle Biotherapeutics
0 jobs at Trestle Biotherapeutics
No open positions
Check back later for new openings